Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2021

Open Access 01-12-2021 | Checkpoint Inhibitors | Review

Deciphering the nonsense-mediated mRNA decay pathway to identify cancer cell vulnerabilities for effective cancer therapy

Authors: Roberta Bongiorno, Mario Paolo Colombo, Daniele Lecis

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Login to get access

Abstract

Nonsense-mediated mRNA decay (NMD) is a highly conserved cellular surveillance mechanism, commonly studied for its role in mRNA quality control because of its capacity of degrading mutated mRNAs that would produce truncated proteins. However, recent studies have proven that NMD hides more complex tasks involved in a plethora of cellular activities. Indeed, it can control the stability of mutated as well as non-mutated transcripts, tuning transcriptome regulation. NMD not only displays a pivotal role in cell physiology but also in a number of genetic diseases. In cancer, the activity of this pathway is extremely complex and it is endowed with both pro-tumor and tumor suppressor functions, likely depending on the genetic context and tumor microenvironment. NMD inhibition has been tested in pre-clinical studies showing favored production of neoantigens by cancer cells, which can stimulate the triggering of an anti-tumor immune response. At the same time, NMD inhibition could result in a pro-tumor effect, increasing cancer cell adaptation to stress. Since several NMD inhibitors are already available in the clinic to treat genetic diseases, these compounds could be redirected to treat cancer patients, pending the comprehension of these variegated NMD regulation mechanisms. Ideally, an effective strategy should exploit the anti-tumor advantages of NMD inhibition and simultaneously preserve its intrinsic tumor suppressor functions. The targeting of NMD could provide a new therapeutic opportunity, increasing the immunogenicity of tumors and potentially boosting the efficacy of the immunotherapy agents now available for cancer treatment.
Literature
1.
Brogna S, Wen J. Nonsense-mediated mRNA decay (NMD) mechanisms. Nat Struct Mol Biol. 2009;16:107–13.PubMedCrossRef
2.
Kurosaki T, Popp MW, Maquat LE. Quality and quantity control of gene expression by nonsense-mediated mRNA decay. Nat Rev Mol Cell Biol. 2019;20:406–20.PubMedPubMedCentralCrossRef
3.
Bokhari A, Jonchere V, Lagrange A, Bertrand R, Svrcek M, Marisa L, et al. Targeting nonsense-mediated mRNA decay in colorectal cancers with microsatellite instability. Oncogenesis. 2018;7:70-018-0079-x.CrossRef
4.
Chang L, Li C, Guo T, Wang H, Ma W, Yuan Y, et al. The human RNA surveillance factor UPF1 regulates tumorigenesis by targeting Smad7 in hepatocellular carcinoma. J Exp Clin Cancer Res. 2016;35:8-016-0286-2.CrossRef
5.
Tani H, Imamachi N, Salam KA, Mizutani R, Ijiri K, Irie T, et al. Identification of hundreds of novel UPF1 target transcripts by direct determination of whole transcriptome stability. RNA Biol. 2012;9:1370–9.PubMedPubMedCentralCrossRef
6.
Yamashita A, Izumi N, Kashima I, Ohnishi T, Saari B, Katsuhata Y, et al. SMG-8 and SMG-9, two novel subunits of the SMG-1 complex, regulate remodeling of the mRNA surveillance complex during nonsense-mediated mRNA decay. Genes Dev. 2009;23:1091–105.PubMedPubMedCentralCrossRef
7.
Kashima I, Yamashita A, Izumi N, Kataoka N, Morishita R, Hoshino S, et al. Binding of a novel SMG-1-Upf1-eRF1-eRF3 complex (SURF) to the exon junction complex triggers Upf1 phosphorylation and nonsense-mediated mRNA decay. Genes Dev. 2006;20:355–67.PubMedPubMedCentralCrossRef
8.
Okada-Katsuhata Y, Yamashita A, Kutsuzawa K, Izumi N, Hirahara F, Ohno S. N- and C-terminal Upf1 Phosphorylations create binding platforms for SMG-6 and SMG-5:SMG-7 during NMD. Nucleic Acids Res. 2012;40:1251–66.PubMedCrossRef
9.
Le Hir H, Izaurralde E, Maquat LE, Moore MJ. The spliceosome deposits multiple proteins 20-24 nucleotides upstream of mRNA exon-exon junctions. EMBO J. 2000;19:6860–9.PubMedPubMedCentralCrossRef
10.
Le Hir H, Gatfield D, Izaurralde E, Moore MJ. The exon-exon junction complex provides a binding platform for factors involved in mRNA export and nonsense-mediated mRNA decay. EMBO J. 2001;20:4987–97.PubMedPubMedCentralCrossRef
11.
Neu-Yilik G, Raimondeau E, Eliseev B, Yeramala L, Amthor B, Deniaud A, et al. Dual function of UPF3B in early and late translation termination. EMBO J. 2017;36:2968–86.PubMedPubMedCentralCrossRef
12.
Wang W, Czaplinski K, Rao Y, Peltz SW. The role of Upf proteins in modulating the translation read-through of nonsense-containing transcripts. EMBO J. 2001;20:880–90.PubMedPubMedCentralCrossRef
13.
Singh G, Rebbapragada I, Lykke-Andersen J. A competition between stimulators and antagonists of Upf complex recruitment governs human nonsense-mediated mRNA decay. PLoS Biol. 2008;6:e111.PubMedPubMedCentralCrossRef
14.
15.
Ivanov A, Mikhailova T, Eliseev B, Yeramala L, Sokolova E, Susorov D, et al. PABP enhances release factor recruitment and stop codon recognition during translation termination. Nucleic Acids Res. 2016;44:7766–76.PubMedPubMedCentralCrossRef
16.
Silva AL, Ribeiro P, Inacio A, Liebhaber SA, Romao L. Proximity of the poly(a)-binding protein to a premature termination codon inhibits mammalian nonsense-mediated mRNA decay. RNA. 2008;14:563–76.PubMedPubMedCentralCrossRef
17.
Amrani N, Ganesan R, Kervestin S, Mangus DA, Ghosh S, Jacobson A. A faux 3′-UTR promotes aberrant termination and triggers nonsense-mediated mRNA decay. Nature. 2004;432:112–8.PubMedCrossRef
18.
Kervestin S, Li C, Buckingham R, Jacobson A. Testing the faux-UTR model for NMD: analysis of Upf1p and Pab1p competition for binding to eRF3/Sup35p. Biochimie. 2012;94:1560–71.PubMedPubMedCentralCrossRef
19.
Eberle AB, Stalder L, Mathys H, Orozco RZ, Muhlemann O. Posttranscriptional gene regulation by spatial rearrangement of the 3′ untranslated region. PLoS Biol. 2008;6:e92.PubMedPubMedCentralCrossRef
20.
21.
22.
23.
Mendell JT, Sharifi NA, Meyers JL, Martinez-Murillo F, Dietz HC. Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise. Nat Genet. 2004;36:1073–8.PubMedCrossRef
24.
Karousis ED, Gypas F, Zavolan M, Muhlemann O. Nanopore sequencing reveals endogenous NMD-targeted isoforms in human cells. Genome Biol. 2021;22:223-021-02439-3.CrossRef
25.
26.
Ni JZ, Grate L, Donohue JP, Preston C, Nobida N, O'Brien G, et al. Ultraconserved elements are associated with homeostatic control of splicing regulators by alternative splicing and nonsense-mediated decay. Genes Dev. 2007;21:708–18.PubMedPubMedCentralCrossRef
27.
Barberan-Soler S, Lambert NJ, Zahler AM. Global analysis of alternative splicing uncovers developmental regulation of nonsense-mediated decay in C. elegans. RNA. 2009;15:1652–60.
28.
Nasif S, Contu L, Muhlemann O. Beyond quality control: the role of nonsense-mediated mRNA decay (NMD) in regulating gene expression. Semin Cell Dev Biol. 2018;75:78–87.PubMedCrossRef
29.
McIlwain DR, Pan Q, Reilly PT, Elia AJ, McCracken S, Wakeham AC, et al. Smg1 is required for embryogenesis and regulates diverse genes via alternative splicing coupled to nonsense-mediated mRNA decay. Proc Natl Acad Sci U S A. 2010;107:12186–91.PubMedPubMedCentralCrossRef
30.
Lou CH, Dumdie J, Goetz A, Shum EY, Brafman D, Liao X, et al. Nonsense-mediated RNA decay influences human embryonic stem cell fate. Stem Cell Reports. 2016;6:844–57.PubMedPubMedCentralCrossRef
31.
Frischmeyer-Guerrerio PA, Montgomery RA, Warren DS, Cooke SK, Lutz J, Sonnenday CJ, et al. Perturbation of Thymocyte development in nonsense-mediated decay (NMD)-deficient mice. Proc Natl Acad Sci U S A. 2011;108:10638–43.PubMedPubMedCentralCrossRef
32.
Gardner LB. Hypoxic inhibition of nonsense-mediated RNA decay regulates gene expression and the integrated stress response. Mol Cell Biol. 2008;28:3729–41.PubMedPubMedCentralCrossRef
33.
Wang D, Zavadil J, Martin L, Parisi F, Friedman E, Levy D, et al. Inhibition of nonsense-mediated RNA decay by the tumor microenvironment promotes tumorigenesis. Mol Cell Biol. 2011;31:3670–80.PubMedPubMedCentralCrossRef
34.
Vattem KM, Wek RC. Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc Natl Acad Sci U S A. 2004;101:11269–74.PubMedPubMedCentralCrossRef
35.
36.
Popp MW, Maquat LE. Attenuation of nonsense-mediated mRNA decay facilitates the response to chemotherapeutics. Nat Commun. 2015;6:6632.PubMedCrossRef
37.
38.
Pastor F, Kolonias D, Giangrande PH, Gilboa E. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature. 2010;465:227–30.PubMedPubMedCentralCrossRef
39.
Oka M, Xu L, Suzuki T, Yoshikawa T, Sakamoto H, Uemura H, et al. Aberrant splicing isoforms detected by full-length transcriptome sequencing as transcripts of potential Neoantigens in non-small cell lung Cancer. Genome Biol. 2021;22:9-020-02240-8.CrossRef
40.
Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, et al. Immuno-genomic landscape of osteosarcoma. Nat Commun. 2020;11:1008-020-14646-w.
41.
Lindeboom RGH, Vermeulen M, Lehner B, Supek F. The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and Cancer immunotherapy. Nat Genet. 2019;51:1645–51.PubMedPubMedCentralCrossRef
42.
El-Bchiri J, Guilloux A, Dartigues P, Loire E, Mercier D, Buhard O, et al. Nonsense-mediated mRNA decay impacts MSI-driven carcinogenesis and anti-tumor immunity in colorectal cancers. PLoS One. 2008;3:e2583.PubMedPubMedCentralCrossRef
43.
El-Bchiri J, Buhard O, Penard-Lacronique V, Thomas G, Hamelin R, Duval A. Differential nonsense mediated decay of mutated mRNAs in mismatch repair deficient colorectal cancers. Hum Mol Genet. 2005;14:2435–42.PubMedCrossRef
44.
Shin N, You KT, Lee H, Kim WK, Song M, Choi HJ, et al. Identification of frequently mutated genes with relevance to nonsense mediated mRNA decay in the high microsatellite instability cancers. Int J Cancer. 2011;128:2872–80.PubMedCrossRef
45.
Becker JP, Helm D, Rettel M, Stein F, Hernandez-Sanchez A, Urban K, et al. NMD Inhibition by 5-Azacytidine Augments Presentation of Immunogenic Frameshift-Derived Neoepitopes. iScience. 2021;24:102389.PubMedPubMedCentralCrossRef
46.
Ionov Y, Nowak N, Perucho M, Markowitz S, Cowell JK. Manipulation of nonsense mediated decay identifies gene mutations in Colon Cancer cells with microsatellite instability. Oncogene. 2004;23:639–45.PubMedCrossRef
47.
Wittmann J, Hol EM, Jack HM. hUPF2 silencing identifies physiologic substrates of mammalian nonsense-mediated mRNA decay. Mol Cell Biol. 2006;26:1272–87.PubMedPubMedCentralCrossRef
48.
Kim WK, Park M, Park M, Kim YJ, Shin N, Kim HK, et al. Identification and selective degradation of Neopeptide-containing truncated mutant proteins in the tumors with high microsatellite instability. Clin Cancer Res. 2013;19:3369–82.PubMedCrossRef
49.
Fan S, Yuan R, Ma YX, Meng Q, Goldberg ID, Rosen EM. Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1. Oncogene. 2001;20:8215–35.PubMedCrossRef
50.
Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Mazoyer S. The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet. 2002;11:2805–14.PubMedCrossRef
51.
Wengrod J, Martin L, Wang D, Frischmeyer-Guerrerio P, Dietz HC, Gardner LB. Inhibition of nonsense-mediated RNA decay activates autophagy. Mol Cell Biol. 2013;33:2128–35.PubMedPubMedCentralCrossRef
52.
53.
Martin L, Gardner LB. Stress-induced inhibition of nonsense-mediated RNA decay regulates intracellular Cystine transport and intracellular glutathione through regulation of the Cystine/glutamate exchanger SLC7A11. Oncogene. 2015;34:4211–8.PubMedCrossRef
54.
Lin W, Wang C, Liu G, Bi C, Wang X, Zhou Q, et al. SLC7A11/xCT in Cancer: biological functions and therapeutic implications. Am J Cancer Res. 2020;10:3106–26.PubMedPubMedCentral
55.
Lewis BP, Green RE, Brenner SE. Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans. Proc Natl Acad Sci U S A. 2003;100:189–92.PubMedCrossRef
56.
Lu J, Plank TD, Su F, Shi X, Liu C, Ji Y, et al. The nonsense-mediated RNA decay pathway is disrupted in inflammatory Myofibroblastic tumors. J Clin Invest. 2016;126:3058–62.PubMedPubMedCentralCrossRef
57.
Cildir G, Low KC, Tergaonkar V. Noncanonical NF-kappaB signaling in health and disease. Trends Mol Med. 2016;22:414–29.PubMedCrossRef
58.
Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, et al. IAP antagonists induce autoubiquitination of C-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell. 2007;131:669–81.PubMedCrossRef
59.
Trumbach D, Pfeiffer S, Poppe M, Scherb H, Doll S, Wurst W, et al. ENCoRE: An efficient software for CRISPR screens identifies new players in extrinsic apoptosis. BMC Genomics. 2017;18:905-017-4285-2.CrossRef
60.
Yang L, Kraft VAN, Pfeiffer S, Merl-Pham J, Bao X, An Y, et al. Nonsense-mediated decay factor SMG7 sensitizes cells to TNFalpha-induced apoptosis via CYLD tumor suppressor and the noncoding oncogene Pvt1. Mol Oncol. 2020;14:2420–35.PubMedPubMedCentralCrossRef
61.
Brumbaugh KM, Otterness DM, Geisen C, Oliveira V, Brognard J, Li X, et al. The mRNA surveillance protein hSMG-1 functions in genotoxic stress response pathways in mammalian cells. Mol Cell. 2004;14:585–98.PubMedCrossRef
62.
Yamashita A, Ohnishi T, Kashima I, Taya Y, Ohno S. Human SMG-1, a novel phosphatidylinositol 3-kinase-related protein kinase, associates with components of the mRNA surveillance complex and is involved in the regulation of nonsense-mediated mRNA decay. Genes Dev. 2001;15:2215–28.PubMedPubMedCentralCrossRef
63.
Delia D, Piane M, Buscemi G, Savio C, Palmeri S, Lulli P, et al. MRE11 mutations and impaired ATM-dependent responses in an Italian family with Ataxia-telangiectasia-like disorder. Hum Mol Genet. 2004;13:2155–63.PubMedCrossRef
64.
Hoek TA, Khuperkar D, Lindeboom RGH, Sonneveld S, Verhagen BMP, Boersma S, et al. Single-molecule imaging uncovers rules governing nonsense-mediated mRNA decay. Mol Cell. 2019;75:324–339.e11.PubMedPubMedCentralCrossRef
65.
Leeksma AC, Derks IAM, Kasem MH, Kilic E, de Klein A, Jager MJ, et al. The effect of SF3B1 mutation on the DNA damage response and nonsense-mediated mRNA decay in Cancer. Front Oncol. 2021;10:609409.PubMedPubMedCentralCrossRef
66.
Te Raa GD, Derks IA, Navrkalova V, Skowronska A, Moerland PD, van Laar J, et al. The impact of SF3B1 mutations in CLL on the DNA-damage response. Leukemia. 2015;29:1133–42.CrossRef
67.
Cheruiyot A, Li S, Nonavinkere Srivatsan S, Ahmed T, Chen Y, Lemacon DS, et al. Nonsense-mediated RNA decay is a unique vulnerability of Cancer cells harboring SF3B1 or U2AF1 mutations. Cancer Res. 2021;81:4499–513.PubMedCrossRef
68.
Miller JN, Pearce DA. Nonsense-mediated decay in genetic disease: friend or foe? Mutat Res Rev Mutat Res. 2014;762:52–64.PubMedCrossRef
69.
Baradaran-Heravi A, Balgi AD, Zimmerman C, Choi K, Shidmoossavee FS, Tan JS, et al. Novel small molecules potentiate premature termination codon Readthrough by aminoglycosides. Nucleic Acids Res. 2016;44:6583–98.PubMedPubMedCentralCrossRef
70.
Dabrowski M, Bukowy-Bieryllo Z, Zietkiewicz E. Translational Readthrough Potential of Natural Termination Codons in Eucaryotes--the Impact of RNA Sequence. RNA Biol. 2015;12:950–8.PubMedPubMedCentralCrossRef
71.
Keeling KM, Brooks DA, Hopwood JJ, Li P, Thompson JN, Bedwell DM. Gentamicin-mediated suppression of hurler syndrome stop mutations restores a Low level of alpha-L-Iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet. 2001;10:291–9.PubMedCrossRef
72.
Usuki F, Yamashita A, Higuchi I, Ohnishi T, Shiraishi T, Osame M, et al. Inhibition of nonsense-mediated mRNA decay rescues the phenotype in Ullrich's disease. Ann Neurol. 2004;55:740–4.PubMedCrossRef
73.
Durand S, Cougot N, Mahuteau-Betzer F, Nguyen CH, Grierson DS, Bertrand E, et al. Inhibition of nonsense-mediated mRNA decay (NMD) by a new chemical molecule reveals the dynamic of NMD factors in P-bodies. J Cell Biol. 2007;178:1145–60.PubMedPubMedCentralCrossRef
74.
Keeling KM, Wang D, Dai Y, Murugesan S, Chenna B, Clark J, et al. Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression. PLoS One. 2013;8:e60478.PubMedPubMedCentralCrossRef
75.
Bhuvanagiri M, Lewis J, Putzker K, Becker JP, Leicht S, Krijgsveld J, et al. 5-Azacytidine inhibits nonsense-mediated decay in a MYC-dependent fashion. EMBO Mol Med. 2014;6:1593–609.PubMedPubMedCentralCrossRef
76.
Gonzalez-Hilarion S, Beghyn T, Jia J, Debreuck N, Berte G, Mamchaoui K, et al. Rescue of Nonsense Mutations by Amlexanox in human cells. Orphanet J Rare Dis. 2012;7:58-1172-7-58.CrossRef
77.
Martin L, Grigoryan A, Wang D, Wang J, Breda L, Rivella S, et al. Identification and characterization of small molecules that inhibit nonsense-mediated RNA decay and suppress nonsense p53 mutations. Cancer Res. 2014;74:3104–13.PubMedPubMedCentralCrossRef
78.
Sabbavarapu NM, Shavit M, Degani Y, Smolkin B, Belakhov V, Baasov T. Design of Novel Aminoglycoside Derivatives with enhanced suppression of diseases-causing nonsense mutations. ACS Med Chem Lett. 2016;7:418–23.PubMedPubMedCentralCrossRef
79.
Bedwell DM, Kaenjak A, Benos DJ, Bebok Z, Bubien JK, Hong J, et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med. 1997;3:1280–4.PubMedCrossRef
80.
Wilschanski M, Famini C, Blau H, Rivlin J, Augarten A, Avital A, et al. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med. 2000;161:860–5.PubMedCrossRef
81.
Politano L, Nigro G, Nigro V, Piluso G, Papparella S, Paciello O, et al. Gentamicin Administration in Duchenne Patients with premature stop codon. Prelim Results Acta Myol. 2003;22:15–21.
82.
Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2014;2:539–47.PubMedCrossRef
83.
Pranke I, Golec A, Hinzpeter A, Edelman A, Sermet-Gaudelus I. Emerging therapeutic approaches for cystic fibrosis. From gene editing to personalized medicine. Front Pharmacol. 2019;10:121.PubMedPubMedCentralCrossRef
84.
Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447:87–91.PubMedCrossRef
85.
Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, et al. Ataluren treatment of patients with nonsense mutation Dystrophinopathy. Muscle Nerve. 2014;50:477–87.PubMedCrossRef
86.
Richardson R, Smart M, Tracey-White D, Webster AR, Moosajee M. Mechanism and evidence of nonsense suppression therapy for genetic eye disorders. Exp Eye Res. 2017;155:24–37.PubMedCrossRef
87.
Krall M, Htun S, Slavotinek A. Use of PTC124 for nonsense suppression therapy targeting BMP4 nonsense variants in vitro and the bmp4st72 allele in zebrafish. PLoS One. 2019;14:e0212121.PubMedPubMedCentralCrossRef
88.
Kerr TP, Sewry CA, Robb SA, Roberts RG. Long mutant dystrophins and variable phenotypes: evasion of nonsense-mediated decay? Hum Genet. 2001;109:402–7.PubMedCrossRef
89.
Linde L, Boelz S, Neu-Yilik G, Kulozik AE, Kerem B. The efficiency of nonsense-mediated mRNA decay is an inherent character and varies among different cells. Eur J Hum Genet. 2007;15:1156–62.PubMedCrossRef
90.
Zetoune AB, Fontaniere S, Magnin D, Anczukow O, Buisson M, Zhang CX, et al. Comparison of nonsense-mediated mRNA decay efficiency in various murine tissues. BMC Genet. 2008;9:83-2156-9-83.CrossRef
91.
Kishor A, Fritz SE, Hogg JR. Nonsense-mediated mRNA decay: the challenge of telling right from wrong in a complex transcriptome. Wiley Interdiscip Rev RNA. 2019;10:e1548.PubMedPubMedCentralCrossRef
92.
Viegas MH, Gehring NH, Breit S, Hentze MW, Kulozik AE. The abundance of RNPS1, a protein component of the exon junction complex, can determine the variability in efficiency of the nonsense mediated decay pathway. Nucleic Acids Res. 2007;35:4542–51.PubMedPubMedCentralCrossRef
93.
Nguyen LS, Wilkinson MF, Gecz J. Nonsense-mediated mRNA decay: inter-individual variability and human disease. Neurosci Biobehav Rev. 2014;46(Pt 2):175–86.PubMedCrossRef
94.
Liu C, Karam R, Zhou Y, Su F, Ji Y, Li G, et al. The UPF1 RNA surveillance gene is commonly mutated in pancreatic Adenosquamous carcinoma. Nat Med. 2014;20:596–8.PubMedPubMedCentralCrossRef
95.
96.
Nicholson P, Yepiskoposyan H, Metze S, Zamudio Orozco R, Kleinschmidt N, Muhlemann O. Nonsense-mediated mRNA decay in human cells: mechanistic insights, functions beyond quality control and the double-life of NMD factors. Cell Mol Life Sci. 2010;67:677–700.PubMedCrossRef
97.
98.
Usuki F, Yamashita A, Kashima I, Higuchi I, Osame M, Ohno S. Specific inhibition of nonsense-mediated mRNA decay components, SMG-1 or Upf1, rescues the phenotype of Ullrich disease fibroblasts. Mol Ther. 2006;14:351–60.PubMedCrossRef
99.
Abraham RT. The ATM-related kinase, hSMG-1, bridges genome and RNA surveillance pathways. DNA Repair (Amst). 2004;3:919–25.CrossRef
100.
101.
Wang D, Wengrod J, Gardner LB. Overexpression of the C-Myc oncogene inhibits nonsense-mediated RNA decay in B lymphocytes. J Biol Chem. 2011;286:40038–43.PubMedPubMedCentralCrossRef
102.
Atanasova VS, Jiang Q, Prisco M, Gruber C, Pinon Hofbauer J, Chen M, et al. Amlexanox enhances premature termination codon read-through in COL7A1 and expression of full length type VII collagen: potential therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2017;137:1842–9.PubMedPubMedCentralCrossRef
103.
104.
Lu SX, De Neef E, Thomas JD, Sabio E, Rousseau B, Gigoux M, et al. Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell. 2021;184:4032–47.e31.
105.
Clifton KK, Ma CX, Fontana L, Peterson LL. Intermittent fasting in the prevention and treatment of Cancer. CA Cancer J Clin. 2021;71:527–46.PubMedCrossRef
106.
Caffa I, Spagnolo V, Vernieri C, Valdemarin F, Becherini P, Wei M, et al. Fasting-mimicking diet and hormone therapy induce breast Cancer regression. Nature. 2020;583:620–4.PubMedPubMedCentralCrossRef
107.
Dai X, Bu X, Gao Y, Guo J, Hu J, Jiang C, et al. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Mol Cell. 2021;81:2317–2331.e6.PubMedCrossRef
108.
Tabrez SS, Sharma RD, Jain V, Siddiqui AA, Mukhopadhyay A. Differential alternative splicing coupled to nonsense-mediated decay of mRNA ensures dietary restriction-induced longevity. Nat Commun. 2017;8:306-017-00370-5.CrossRef
109.
Wang M, Zhang P, Zhu Y, Kong X, Zhang Z, Hu L. Assessing the activity of nonsense-mediated mRNA decay in lung Cancer. BMC med. Genomics. 2017;10:55-017-0292-z.
110.
Jayasinghe RG, Cao S, Gao Q, Wendl MC, Vo NS, Reynolds SM, et al. Systematic analysis of splice-site-creating mutations in Cancer. Cell Rep. 2018;23:270–81 e3.PubMedPubMedCentralCrossRef
111.
Kahles A, Lehmann KV, Toussaint NC, Huser M, Stark SG, Sachsenberg T, et al. Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell. 2018;34:211–24 e6.PubMedCrossRef
112.
Smart AC, Margolis CA, Pimentel H, He MX, Miao D, Adeegbe D, et al. Intron retention is a source of Neoepitopes in Cancer. Nat Biotechnol. 2018;36:1056–8.PubMedPubMedCentralCrossRef
Metadata
Title
Deciphering the nonsense-mediated mRNA decay pathway to identify cancer cell vulnerabilities for effective cancer therapy
Authors
Roberta Bongiorno
Mario Paolo Colombo
Daniele Lecis
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-021-02192-2

Other articles of this Issue 1/2021

Journal of Experimental & Clinical Cancer Research 1/2021 Go to the issue

Research

Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma

Research

Linc-SCRG1 accelerates progression of hepatocellular carcinoma as a ceRNA of miR26a to derepress SKP2

Research

Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer

Correction

Correction to: Genistein inhibits stemness of SKOV3 cells induced by macrophages co-cultured with ovarian cancer stem-like cells through IL-8/STAT3 axis

Review

Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development

Review

Gut microbiota influence tumor development and Alter interactions with the human immune system
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits